Although the abovementioned advantages highlight that DUB inhibitors are potential cancer therapeutics, several challenges and unsolved problems warrant attention and intensive research.(i)Deubiquitination is an intracellular biological process; thus, unlike small-molecule compounds, therapeutic antibodies cannot bind DUBs [143]. This evidence concerns the gene ZUP1 and cancer.